{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:32:05Z","timestamp":1793831525319,"version":"4.6.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014756","name":"Hexal AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014756","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Denosumab is a monoclonal antibody used to reduce risk of fractures in osteoporosis. ROSALIA was a multicenter, double-blind, randomized, integrated phase I\/phase III study comparing the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and safety of proposed biosimilar denosumab GP2411 with reference denosumab (REF-DMAb) (Prolia\u00ae; Amgen). Postmenopausal women with osteoporosis were randomized 1:1 to 2 60-mg doses of GP2411 or REF-DMAb, one at study start and one at week 26. At week 52, the REF-DMAb group was re-randomized 1:1 to a third dose of REF-DMAb or switch to GP2411. The primary efficacy endpoint was percentage change from baseline (%CfB) in LS-BMD at week 52. Secondary efficacy endpoints were %CfB in LS-BMD, FN-BMD, and TH-BMD at weeks 26 and 78 (and week 52 for FN-BMD and TH-BMD). Primary PK and PD endpoints were the area under the serum concentration\u2013time curve extrapolated to infinity and maximum drug serum concentration at week 26, and the area under the effect\u2013time curve of the %CfB in serum CTX at week 26. Secondary PK and PD endpoints included drug serum concentrations and %CfB in serum CTX and P1NP during the study period. Similar efficacy was demonstrated at week 52, with 95% CIs of the difference in %CfB in LS-BMD between treatment groups fully contained within prespecified equivalence margins. Similarity in PK and PD was demonstrated at week 26. Immunogenicity was similar between groups and was not impacted by treatment switch. The rate of new vertebral fractures was comparable. Treatment-emergent adverse events were comparable between groups (63.6% [GP2411\/GP2411]; 76.0% [REF-DMAb\/REF-DMAb]; 76.6% [REF-DMAb\/GP2411]). In conclusion, ROSALIA showed similar efficacy, PK and PD, and comparable safety and immunogenicity of GP2411 to REF-DMAb in postmenopausal osteoporosis.<\/jats:p>","DOI":"10.1093\/jbmr\/zjae016","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T12:08:00Z","timestamp":1706530080000},"page":"202-210","source":"Crossref","is-referenced-by-count":24,"title":["Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study"],"prefix":"10.1093","volume":"39","author":[{"given":"S\u0142awomir","family":"Jeka","sequence":"first","affiliation":[{"name":"Clinic and Department of Rheumatology and Systemic Diseases of Connective Tissue, University Hospital No. 2. Bydgoszcz, CM UMK, 85-168 Bydgoszcz, KP, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Dokoupilov\u00e1","sequence":"additional","affiliation":[{"name":"Medical Plus, s.r.o. , 68601 Uherske Hradiste, ZL, Czech Republic"},{"name":"Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology , 612 00 Brno, JM, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Kivitz","sequence":"additional","affiliation":[{"name":"Altoona Center for Clinical Research , Duncansville, PA 16635, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"\u017buchowski","sequence":"additional","affiliation":[{"name":"Clinic and Department of Rheumatology and Systemic Diseases of Connective Tissue , University Hospital No. 2. Bydgoszcz, CM UMK, 85-168 Bydgoszcz, KP, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Vogg","sequence":"additional","affiliation":[{"name":"Clinical Development Biopharmaceuticals, Hexal AG , 83607 Holzkirchen, BY, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Krivtsova","sequence":"additional","affiliation":[{"name":"Clinical Development Biopharmaceuticals, Hexal AG , 83607 Holzkirchen, BY, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susmit","family":"Sekhar","sequence":"additional","affiliation":[{"name":"Clinical Development Biopharmaceuticals, Hexal AG , 83607 Holzkirchen, BY, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samik","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Clinical Development Biopharmaceuticals, Hexal AG , 83607 Holzkirchen, BY, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnd","family":"Schwebig","sequence":"additional","affiliation":[{"name":"Clinical Development Biopharmaceuticals, Hexal AG , 83607 Holzkirchen, BY, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Poetzl","sequence":"additional","affiliation":[{"name":"Clinical Development Biopharmaceuticals, Hexal AG , 83607 Holzkirchen, BY, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Body","sequence":"additional","affiliation":[{"name":"University Hospital Brugmann, Universit\u00e9 Libre de Bruxelles (ULB) Department of Medicine, , 1020 Brussels, BE, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[{"name":"University of Sheffield Division of Clinical Medicine, , Sheffield S10 2TN, SYK, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"key":"2024052213404238900_ref1","volume-title":"Prolia\u00ae (Denosumab). European Medicines Agency SmPC","year":"2022"},{"key":"2024052213404238900_ref2","volume-title":"Prolia\u00ae (Denosumab) [Package Insert]","year":"2023"},{"key":"2024052213404238900_ref3","volume-title":"Xgeva\u00ae (Denosumab) [Package Insert]","year":"2022"},{"key":"2024052213404238900_ref4","volume-title":"Xgeva\u00ae (Denosumab). European Medicines Agency SmPC","year":"2020"},{"issue":"1","key":"2024052213404238900_ref5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","article-title":"Denosumab in the treatment of osteoporosis: 10 years later: a narrative review","volume":"39","author":"Kendler","year":"2022","journal-title":"Adv Ther"},{"key":"2024052213404238900_ref6","volume-title":"Common Drug Review Pharmacoeconomic Report for Prolia [Internet]","author":"Canadian Agency for Drugs and Technologies in Health","year":"2015"},{"issue":"1","key":"2024052213404238900_ref7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12962-016-0060-5","article-title":"What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia","volume":"14","author":"Karnon","year":"2016","journal-title":"Cost Eff Resour Alloc"},{"key":"2024052213404238900_ref8","doi-asserted-by":"crossref","first-page":"151939","DOI":"10.1016\/j.semarthrit.2021.11.009","article-title":"The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems","volume":"52","author":"Kvien","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2024052213404238900_ref9","volume-title":"Scientific Considerations in Demonstrating Biosimilarity to a Reference Product","author":"U.S. Food and Drug Administration","year":"2015"},{"issue":"26","key":"2024052213404238900_ref10","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2012-04-425744","article-title":"Biosimilars: what clinicians should know","volume":"120","author":"Weise","year":"2012","journal-title":"Blood"},{"key":"2024052213404238900_ref11","volume-title":"Biosimilars in the EU. Information Guide for Healthcare Professionals","author":"European Medicines Agency","year":"2019"},{"issue":"2","key":"2024052213404238900_ref12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos Int"},{"issue":"8","key":"2024052213404238900_ref13","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"2024052213404238900_ref14","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2024052213404238900_ref15","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"2024052213404238900_ref16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10928-015-9422-4","article-title":"Using early biomarker data to predict long-term bone mineral density: application of semi-mechanistic bone cycle model on denosumab data","volume":"42","author":"Zheng","year":"2015","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"12","key":"2024052213404238900_ref17","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2165\/11594240-000000000-00000","article-title":"Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis","volume":"50","author":"Sutjandra","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2024052213404238900_ref18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1208\/s12248-019-0386-y","article-title":"Recommendations for the development and validation of immunogenicity assays in support of biosimilar programs","volume":"22","author":"Civoli","year":"2020","journal-title":"AAPS J."},{"key":"2024052213404238900_ref19","volume-title":"Immunogenicity Testing of Therapeutic Protein Products \u2014 Developing and Validating Assays for Anti-Drug Antibody Detection","author":"FDA","year":"2019"},{"issue":"7","key":"2024052213404238900_ref20","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2024052213404238900_ref21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3390\/biologics2030014","article-title":"Biosimilars: harmonizing the approval guidelines","volume":"2","author":"Niazi","year":"2022","journal-title":"Biologics"},{"issue":"1","key":"2024052213404238900_ref22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamainternmed.2020.3997","article-title":"Assessment of availability, clinical testing, and US Food and Drug Administration review of biosimilar biologic products","volume":"181","author":"Moore","year":"2021","journal-title":"JAMA Intern Med"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjae016\/56993058\/zjae016.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/39\/3\/202\/57805287\/zjae016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/39\/3\/202\/57805287\/zjae016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T16:30:51Z","timestamp":1716395451000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/39\/3\/202\/7591122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,1,29]]},"published-print":{"date-parts":[[2024,4,19]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjae016","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2024,1,29]]}}}